CBM F1
Alternative Names: CBM-F1Latest Information Update: 02 Jan 2023
At a glance
- Originator CellionBioMed
- Class Antineoplastics
- Mechanism of Action Small-conductance calcium-activated potassium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer; Pancreatic cancer
Most Recent Events
- 29 Dec 2022 CBM F1 is still in preclinical trial for Liver cancer in South Korea (CellionBioMed pipeline, December 2022)
- 29 Dec 2022 CBM F1 is still in preclinical trial for Pancreatic cancer in South Korea (CellionBioMed pipeline, December 2022)
- 21 Jun 2022 Preclinical trials in Liver cancer in South Korea (unspecified route), prior to June 2022 (CellionBioMed pipeline, June 2022)